Rubicon Research (RUBICON) Q2 25/26 earnings summary

Executive summary

• Standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025, were approved and reviewed by the Audit Committee and Board of Directors.

• The company completed an IPO post-quarter, raising ₹13,775 million and listing on NSE and BSE on October 16, 2025.

Financial highlights

• Standalone revenue from operations for Q2 FY26 was ₹3,364.67 million, up from ₹2,548.98 million in Q2 FY25; consolidated revenue was ₹4,120.18 million, up from ₹2,960.10 million year-over-year.

• Standalone net profit for Q2 FY26 was ₹458.12 million, compared to ₹428.87 million in Q2 FY25; consolidated net profit was ₹538.52 million, up from ₹344.78 million year-over-year.

• Standalone EPS for the quarter was ₹2.97 (basic), up from ₹2.82 year-over-year; consolidated EPS was ₹3.49 (basic), up from ₹2.27 year-over-year.

• Standalone total comprehensive income for Q2 FY26 was ₹454.49 million; consolidated total comprehensive income was ₹470.77 million.

Outlook and guidance

• The company is focused on expanding its pharmaceutical product sales and has entered into agreements to invest in Gen1e Lifesciences Inc. and Neuronasal Inc. post-quarter.